Literature DB >> 29103417

Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis.

Xuan Liu1, Li-Juan Xiu1, Jian-Peng Jiao1, Jing Zhao1, Ying Zhao1, Ye Lu1, Jun Shi1, Yong-Jin Li1, Min Ye1, Yu-Fang Gu1, Xiao-Wei Wang1, Jing-Yu Xu1, Ci-An Zhang1, Yong-Ying Liu1, Yun Luo1, Xiao-Qiang Yue1.   

Abstract

OBJECTIVE: Traditional Chinese medicine (TCM) is regarded as an important treatment for gastric cancer patients, especially for those in advanced stage. To evaluate the effects of TCM treatment on gastric cancer patients, the authors performed a retrospective study to report the result of the integrated treatment of TCM with chemotherapy for stage IV non-surgical gastric cancer.
METHODS: In this study, 182 patients with stage IV and non-surgical gastric cancer were retrospectively analyzed to evaluate the effects of TCM integrated with chemotherapy. Among the 182 cases, 88 cases received integrated therapy consisting of TCM and chemotherapy, while 94 cases received chemotherapy alone. The overall survival and Karnofsky performance status (KPS) score were measured as the main outcome.
RESULTS: The median overall survival of the integrated therapy group and chemotherapy group were 16.9 and 10.5 months, respectively. The 1-, 3- and 5-year survival rates of integrated therapy group vs. chemotherapy group were 70% vs. 32%, 18% vs. 4%, and 11% vs. 0%, respectively. There was a significant difference between the two groups (χ2 = 42.244, P > 0.001). After six-month treatment, KPS scores of the integrated therapy group and the chemotherapy group were 75.00 ± 14.78 and 60.64 ± 21.39, respectively (P > 0.001). The Cox regression analysis showed that TCM treatment is a protective factor for patients' overall survival.
CONCLUSION: This study demonstrated that TCM integrated with chemotherapy may prolong overall survival and improve survival rate and life quality of patients with stage IV non-surgical gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29103417     DOI: 10.1016/S2095-4964(17)60377-7

Source DB:  PubMed          Journal:  J Integr Med


  17 in total

1.  Pathological analysis of the superior mesenteric artery boundary in preoperative computed tomography of resectable pancreatic head adenocarcinoma.

Authors:  Meng Lu; Chun-Hui Yuan; Ling-Fu Zhang; Lian-Yuan Tao; Ying Peng; Li-Mei Guo; Gang Li; Dian-Rong Xiu
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

2.  Effect of Hematocrit Injury on the Survival Rate of Advanced Malignant Tumors and Its Clinical Significance.

Authors:  Lin Li; Weibin Wu; Mingdi Yin
Journal:  Comput Math Methods Med       Date:  2022-06-15       Impact factor: 2.809

3.  Neferine induces mitochondrial dysfunction to exert anti-proliferative and anti-invasive activities on retinoblastoma.

Authors:  Jing Wang; Yanmin Dong; Qiuming Li
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-28

4.  LncRNA WWOX‑AS1 inhibits the proliferation, migration and invasion of osteosarcoma cells.

Authors:  Gang Qu; Zhiqiang Ma; Wenxian Tong; Jiahui Yang
Journal:  Mol Med Rep       Date:  2018-05-23       Impact factor: 2.952

5.  Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis.

Authors:  Xiaoli Liu; Mengge Li; Xinhui Wang; Zhibo Dang; Yuyong Jiang; Xianbo Wang; Zhiyun Yang
Journal:  Lipids Health Dis       Date:  2018-11-06       Impact factor: 3.876

6.  miR-125a restrains cell migration and invasion by targeting STAT3 in gastric cancer cells.

Authors:  Liu Yang; Shuguang Zhang; Kai Guo; Hu Huang; Shuai Qi; Jie Yao; Zhihong Zhang
Journal:  Onco Targets Ther       Date:  2018-12-24       Impact factor: 4.147

7.  Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.

Authors:  Bili Wang; Can Shen; Yang Li; Ting Zhang; Hui Huang; Jun Ren; Zhengjun Hu; Jian Xu; Bin Xu
Journal:  Onco Targets Ther       Date:  2019-07-17       Impact factor: 4.147

8.  Effect of Yiqi Huayu Jiedu decoction on stages II and III gastric cancer: A multicenter, prospective, cohort study.

Authors:  Peng Shu; Huijuan Tang; Bin Zhou; Ruiping Wang; Yuanyuan Xu; Jie Shao; Minghao Qi; Yun Xia; Wenjie Huang; Shenlin Liu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

9.  ZiYinHuaTan Recipe Inhibits Cell Proliferation and Promotes Apoptosis in Gastric Cancer by Suppressing PI3K/AKT Pathway.

Authors:  Jiahui Yu; Shangjin Song; Jianpeng Jiao; Xuan Liu; Huirong Zhu; Lijuan Xiu; Dazhi Sun; Qi Li; Xiaoqiang Yue
Journal:  Biomed Res Int       Date:  2020-04-22       Impact factor: 3.411

10.  A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail.

Authors:  Xiaoting Pan; Heyun Tao; Mengjun Nie; Yuanjie Liu; Pan Huang; Shenlin Liu; Wei Sun; Jian Wu; Ting Ma; Anwei Dai; Jianwei Lu; Baorui Liu; Xi Zou; Qingmin Sun
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.